BlossomHill Therapeutics Q2 R&D Spending Jumps as Newly Public Biotech Advances Cancer Pipeline
BlossomHill Therapeutics, Inc. reported a sharp increase in second-quarter research spending as the newly listed biotechnology company expanded clinical develop